Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kayleigh Kew
Axitinib, Cabozantinib, Everolimus, Nivolumab, Sunitinib and Best Supportive Care in Previously Treated Renal Cell Carcinoma: A Systematic Review and Economic Evaluation
Health Technology Assessment
Medicine
Health Policy
Related publications
Bevacizumab, Sorafenib Tosylate, Sunitinib and Temsirolimus for Renal Cell Carcinoma: A Systematic Review and Economic Evaluation
Health Technology Assessment
Medicine
Health Policy
Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma
European Urology
Urology
Pcn17 - Indirect Treatment Comparisons of Nivolumab Versus Regorafenib, Cabozantinib and Best Supportive Care After Treatment With Sorafenib for Hepatocellular Carcinoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Spotlight on Cabozantinib for Previously Untreated Advanced Renal Cell Carcinoma: Evidence to Date
Cancer Management and Research
Oncology
Pharmacoeconomic Evaluation of Axitinib Introduction in Metastatic Renal Cell Carcinoma Treatment Scheme
Pharmacoeconomics: theory and practice
Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
A Case of Metastatic Renal Cell Carcinoma and Bile Duct Carcinoma Treated With a Combination of Sunitinib and Gemcitabine
BMC Cancer
Cancer Research
Oncology
Genetics
Axitinib Plus Pembrolizumab Is Effective in Renal Cell Carcinoma
Cancer Discovery
Oncology
